Cargando…
Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway
BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in type 2 diabetes therapy, has demonstrated protective effects in diabetic chronic kidney disease, in part due to its pleiotropic actions. However, its potential direct effects on the kidney are still not completely defined. H...
Autores principales: | Civantos, Esther, Bosch, Enrique, Ramirez, Elisa, Zhenyukh, Olha, Egido, Jesús, Lorenzo, Oscar, Mas, Sebastián |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473486/ https://www.ncbi.nlm.nih.gov/pubmed/28652790 http://dx.doi.org/10.2147/DMSO.S132537 |
Ejemplares similares
-
Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis
por: Fan, Z, et al.
Publicado: (2017) -
Nomilin targets the Keap1‐Nrf2 signalling and ameliorates the development of osteoarthritis
por: Xue, Xing‐He, et al.
Publicado: (2020) -
Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway
por: Wang, Dongdong, et al.
Publicado: (2018) -
Branched‐chain amino acids promote endothelial dysfunction through increased reactive oxygen species generation and inflammation
por: Zhenyukh, Olha, et al.
Publicado: (2018) -
Keap1-Nrf2 Heterodimer: A Therapeutic Target to Ameliorate Sickle Cell Disease
por: Chauhan, Waseem, et al.
Publicado: (2023)